Editors' Response to Johnson

Hooper, David C.; Hirsch, Martin S.
September 2014
Journal of Infectious Diseases;Sep2014, Vol. 210 Issue 6, p993
Academic Journal
Letter to the Editor
A response from the editor related to articles regarding the purported new botulinum neurotoxin serotype H published in a 2014 issue is presented.


Related Articles

  • Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Ã… resolution. Hanson, Michael A.; Stevens, Raymond C. // Nature Structural Biology;Aug2000, Vol. 7 Issue 8, p687 

    Botulinum neurotoxin serotype B is a zinc protease that disrupts neurotransmitter release by cleaving synaptobrevin-II (Sb2), one of three SNARE proteins involved in neuronal synaptic vesicle fusion. The three-dimensional crystal structure of the apo botulinum neurotoxin serotype B catalytic...

  • Uses of botulinum toxin injection in medicine today. Munchau, A.; Bhatia, K. P. // BMJ: British Medical Journal (International Edition);01/15/2000, Vol. 320 Issue 7228, p161 

    Discusses the uses of botulinum toxin injection in modern medicine. Mode of action; Rationale for treatment with botulinum neurotoxin; Side effects of the toxin; Indications for treatment.

  • The many faces of botox. Cohen, Sharon; Kallen, Ben // Shape;Jul2004, Vol. 23 Issue 11, p93 

    Reports on various uses of botulinum toxin.

  • Moving across membranes. Neale, Elaine A. // Nature Structural Biology;Jan2003, Vol. 10 Issue 1, p2 

    Discusses results from studies on botulinum neurotoxin which suggested that the toxin heavy chain function as both a channel and a chaperone for translocation of the catalytically active light chain. Agents that blocked toxin-induced inhibition of neurotransmitter release; Protein toxins that...

  • Response to Rupp and Segelke. Stevens, Raymond; Hanson, Michael // Nature Structural Biology;Aug2001, Vol. 8 Issue 8, p664 

    Responds to a commentary on an article which reported the cocrystal structure of the botulinum neurotoxin B light chain in complex with a 38-residue target peptide of synaptobrevin II. Clarification on peptide estimation; Observation on the outcome of translocation domain separation.

  • Validity of Botulinum Neurotoxin Serotype H. Johnson, Eric A. // Journal of Infectious Diseases;Sep2014, Vol. 210 Issue 6, p992 

    A letter to the editor is presented in response to several articles and commentaries regarding the purported new botulinum neurotoxin serotype H published in 2014 issue.

  • DNA Vaccination Using the Fragment C of Botulinum Neurotoxin Type A Provided Protective Immunity in Mice. Shyu, Rong-Hwa; Shaio, Men-Fang; Tang, Shiao-Shek; Shyu, Huey-Fen; Lee, Chi-Feng; Tsai, Meng-Hung; Smith, Jason E.; Huang, Hsin-Hsien; Wey, Jiunn-Jye; Huang, Jan-Ling; Chang, Hsin-Hou // Journal of Biomedical Science;2000, Vol. 7 Issue 1, p51 

    Botulinum neurotoxin (BoNT) is one of the most toxic substances known to produce severe neuromuscular paralysis. The currently used vaccine is prepared mainly from biohazardous toxins. Thus, we studied an alternative method and demonstrated that DNA immunization provided sufficient protection...

  • Possible link between botulinum toxin and Key-Gaskell syndrome in cats.  // Veterinary Record: Journal of the British Veterinary Association;7/24/2004, Vol. 155 Issue 4, p102 

    Focuses on the link possible link between botulinum toxin and Key-Gaskell syndrome in cats.

  • Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Koriazova, Lilia K.; Montal, Mauricio // Nature Structural Biology;Jan2003, Vol. 10 Issue 1, p13 

    Clostridial botulinum neurotoxins (BoNTs) abort the process of neurotransmitter release at presynaptic motor nerve terminals, causing muscle paralysis. An enigmatic step in the intoxication process is the mechanism by which the neurotoxin heavy chain (HC) forms the conduit for the translocation...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics